Loading clinical trials...

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Trials | Clareo Health

TERMINATEDPhase 3

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04128696•GlaxoSmithKline

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Neoplasms, Head and Neck

Interventions

feladilimab

Pembrolizumab

+1 more

Locations

163

United States

Locations (163)

GSK Investigational Site

Duarte, California, United States

GSK Investigational Site

Washington D.C., District of Columbia, United States

GSK Investigational Site

St. Petersburg, Florida, United States

GSK Investigational Site

Indianapolis, Indiana, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Charlotte, North Carolina, United States

Key Dates

Start Date

November 21, 2019

Primary Completion Date

April 27, 2021

Completion Date

June 20, 2023

Last Updated

July 10, 2024

Related Studies

COMPLETEDPhase 2

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684

Cancer of Head and NeckHead and Neck Cancer+4 more

Head and Neck Cancer in Children: A Retrospective Study

NCT02557048

Head and Neck NeoplasmsCancer of Head and Neck+3 more

TERMINATEDPhase 1

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell+18 more

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators

Merck Sharp & Dohme LLC

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 10, 2024Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions